A method to further scale up the large-scale production of oncolytic H-1 protoparvovirus (H-1PV) using a carrier-based production process in combination with optimized cell culture media.

The method optimizes large-scale production of oncolytic protoparvovirus H-1PV using VP-SFM™ medium, non-synchronous seeding, and a three-step medium exchange, along with environmentally friendly lysis buffers, to achieve high yields and reduce costs by minimizing FBS and animal-derived products.

JP7946640B2Active Publication Date: 2026-11-09DEUTES KREBSFORSCHUNGSZENT STIFTUNG DES OFFENTLICHEN RECHTS
4 Cites 0 Cited by

Patent Information

Application Number
JP2024518997
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Filing Date
2022-09-28
Publication Date
2026-11-09
Estimated Expiration
2042-09-28

AI Technical Summary

Technical Problem

Current methods for producing oncolytic protoparvovirus H-1PV on a large scale do not achieve high viral yield while simultaneously reducing production costs and avoiding undesirable animal-derived products.

Method used

The method employs VP-SFM™ cell culture medium, a non-simultaneous seeding and infection process, and a three-step medium exchange strategy to reduce FBS usage, along with the use of microcarriers and macrocarriers optimized for cell proliferation and virus production, and an environmentally friendly lysis buffer containing Tris, MgCl2, and TrypLE® instead of Triton® X-100.

Benefits of technology

This approach achieves high virus production yields with reduced impurities and costs by minimizing FBS use and avoiding animal-derived components, while maintaining effective virus recovery and production efficiency.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007946640000005
    Figure 0007946640000005
  • Figure 0007946640000006
    Figure 0007946640000006
  • Figure 0007946640000007
    Figure 0007946640000007
Patent Text Reader

Abstract

The present invention provides a method for large-scale parvovirus production, preferably upstream optimization of oncolytic protoparvovirus H-1 (H-1PV). The method is based on the use of micro- or macrocarriers and suspension or fixed bed, respectively, optimized cell culture medium and medium exchange strategy. In summary, with optimized cell culture medium and novel medium exchange strategy, the inventors established seeded cell density and animal serum reduction, resulting in animal serum-free harvests. The tested carriers were the most suitable for high H-1PV yields, cell growth and bead-to-bead transfer capacity, and the inventors further scaled up the process from 24-well plates to Erlenmeyer flasks, spinner flasks and iCellis Nano. In conclusion, the present invention provides a large-scale method to produce oncolytic protoparvovirus H-1 with high virus yields, while at the same time lowering production costs and avoiding undesired products of animal origin.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical Field]

[0001] This invention provides an upstream optimization method for large-scale parvovirus production, preferably for oncolytic protoparvovirus H-1 (H-1PV). The method is based on the use of microcarriers or macrocarriers and suspensions or fixed beds, respectively, optimized cell culture media, and a novel medium exchange strategy. In summary, using optimized cell culture media and a novel medium exchange strategy, the inventors established seeded cell density and reduced animal serum, resulting in animal serum-free recoveries. The carriers tested were best suited for high H-1PV yield, cell proliferation, and bead-to-bead transfer ability, and the inventors further tested products in Erlenmeyer flasks, spinner flasks, and iCellis nano. In conclusion, this invention provides a large-scale method for producing oncolytic protoparvovirus H-1 with high viral yield while simultaneously reducing production costs and avoiding undesirable animal-derived products. [Background technology]

[0002] According to the World Health Organization (WHO), cancer was the second leading cause of death worldwide in 2018, killing an estimated 9.6 million people. Economic losses associated with cancer are significant and increasing, totaling approximately $1.16 trillion in 2010 alone (Stewart 2014). Viral (OV) therapy is a promising approach to treating this disease. OV are genetically modified or naturally occurring viruses that selectively destroy cancer cells without harming healthy tissue (Fukuhara 2016). In 2015, the first OV treatment (T-VEC or Imlygic™) was approved by the FDA, followed some time later by the EMA. Other OV treatments based on different viral platforms (https: / / webs.iiitd.edu.in / raghava / ovirustdb / clinical.php) are also in the development pipeline.

[0003] The OV drug "ParvOryx®" utilizes wild-type parvovirus H-1PV belonging to the genus Protoparvovirus of the subfamily Parvovirinae, family Parvoviridae (Cotmore 2014). This virus demonstrated oncolytic and tumor-suppressing properties during preclinical proof-of-concept studies in various cultured cell lines, animal experiments (Rommelaere 2010; Nuesch 2012), and xenograft models for several human tumor species (Geletneky 2010; Faisst 1998; Angelova 2009b; Dupressoir 1989; Angelova 2009a). H-1PV also demonstrated safety and immunogenicity in Phase I / IIa clinical trials (Geletneky 2012; Geletneky 2017) and Phase II trials (Hajda 2021).

[0004] Therefore, treatment of patients with oncolytic protoparvovirus H-1PV has shown promising results in clinical trials for several types of cancer (Hajda 2021; Geletneky 2017). However, in preparation for the future market release of H-1PV, the culture media and production processes need to be adapted and optimized for robust, controlled, large-scale systems, namely those with system parameters such as agitation rate, aeration, seeding cell density, infection timing, infection multiplicity, harvesting timing, and harvesting strategy.

[0005] Therefore, refer to, for example, European Patent No. 3313987, concerning a method for producing parvovirus particles using the NB-324K cell line, which uses a cell culture medium containing animal components for large-scale virus production. To remove unwanted contaminants such as animal-derived components, an improved purification of infectious particles has been introduced, which is based on a two-step iodixanol density gradient ultracentrifugation process, first in PBS and second in Ringer's. Furthermore, European Patent Application EP17771376.5 describes a further optimized process for parvovirus production, primarily based on the VP-SFM™ cell culture medium free of animal components, which makes the production and purification of parvovirus produced by NB-324K cells easier and more cost-effective.

[0006] However, none of the approaches provided a large-scale method for producing oncolytic protoparvovirus H-1 with high viral yield while simultaneously reducing production costs and avoiding undesirable animal-derived products.

[0007] Therefore, the fundamental technical problem underlying the present invention is to further optimize the large-scale production of parvovirus.

[0008] This solution is achieved by providing embodiments as described in the claims. [Overview of the Initiative] [Problems that the invention aims to solve]

[0009] Treatment of patients with oncolytic protoparvovirus H-1PV has shown promising results in clinical trials for several types of cancer (Hajda 2021; Geletneky 2017). These data represent the first results of producing H-1PV in a large-scale bioreactor system. However, this process needs to be adapted and optimized according to system parameters such as agitation rate, aeration, seeding cell density, infection timing, infection multiplicity, and harvesting time.

[0010] Firstly, the cell culture media mentioned earlier require supplementation with animal serum, as it is essential for stimulating cell proliferation, metabolism, and growth. Therefore, the addition of animal serum, such as fetal bovine serum (FBS), to cell culture remains common, but there are issues in terms of quality, lot-to-lot reproducibility, animal welfare, supply, cost (vanderValk2018), and potential future regulatory restrictions. [Means for solving the problem]

[0011] Therefore, the method of the present invention uses VP-SFM™ (Liu 2017; Rourou 2007; Martinez 2020), an optimized culture medium suitable for FBS-free parvovirus production, and at least two-step medium exchange strategies to reduce the amount of FBS required for FBS-free recovery by up to 80% with equivalent virus yield. By adding medium exchanges and reducing FBS in three steps, for example from 2% to 1% and then to 0%, an increase in production of approximately 0.3 log was achieved compared to a reduction of FBS from 2% to 0% and a subsequent second reduction to 0%, and the required FBS could be reduced by up to 40%. By applying at least two-step medium exchange strategies, preferably three-step medium exchange strategies, in experiments resulting from the present invention, high virus production yields and fewer impurities for downstream processes could be achieved in the FBS-free recovery.

[0012] Furthermore, using the method according to the present invention, more specifically, a non-simultaneous seeding and infection process, the seeding density is set to 7.9E3 cells / cm². 2 From 5.0E3 cells / cm 2 This allowed for a reduction in viral yield, while maintaining similar levels of viral output after adaptation to VP-SFM (trademark). In this way, the growth time could be shortened, reducing the resources required for seed training and thus lowering the cost of cell production.

[0013] Furthermore, conventional techniques commonly utilize microcarriers for suspension culture or macrocarriers for fixed-bed bioreactors for large-scale H-1PV production using adherent cells such as the H-1PV-producing cell line NB-324K. Large-scale production methods make the previously used freeze-thaw cycle impractical; therefore, the present invention is implemented without the need for trypsin treatment and freeze-thaw cycles. Instead, the inventors previously introduced Triton® X-100 (key component: 2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethanol)-based chemical cell lysis. Dissolution with Triton® X-100 has achieved satisfactory production yields with various microcarriers and macrocarriers. However, the surfactant Triton® X-100 is currently considered environmentally toxic by regulatory authorities (https: / / echa.europa.eu / authorisation-list). Therefore, in one embodiment of the present invention, a lysis buffer containing Tris, MgCl2, and recombinant cell dissociation enzyme TrypLE® together with Tween® 80 is tested as an alternative lysis buffer because this buffer is more environmentally friendly than Triton® X-100 buffer and allows for the omission of Tween® 80 from the lysis buffer recipe without adversely affecting the virus yield.

[0014] In experiments leading to the present invention, several microcarriers and macrocarriers were tested. First, in one embodiment of the present invention, the solid microcarrier Cytodex® 1, which is a crosslinked dextran matrix having positively charged DEAE (N,N-diethylaminoethyl) groups distributed throughout the matrix, has been found to be well-suited for large-scale production or adhesion-enhanced CellBIND® (EA) microcarriers. The adhesion-enhanced CellBIND® (EA) microcarriers have a negative surface charge due to oxygen-containing functional groups incorporated into the polystyrene surface. These microcarriers have shown promising inter-bead cell migration capabilities during cell proliferation and virus production. To date, Cytodex® 1 has been reported for adenoviruses and retroviruses (Wu 2002), vaccinia virus (Liu 2017), and influenza virus A (Tree 2001).

[0015] Alternative embodiments of the method of the present invention are represented by polypropylene and polyester nonwoven fibers (Fibra-Cel®) or nonwoven hydrophilic polyethylene terephthalate (PET) macrocarriers (iCELLis®) because their use results in good production yields in suspension cultures, and these macrocarriers are also designed for fixed-bed bioreactors where higher yields can be achieved.

[0016] In summary, in the experiments resulting from this invention, the inventors optimized the cell culture medium and applied a novel medium exchange strategy. Finally, they established a reduction in seeding cell density and animal serum supplementation, resulting in a recovery free of animal components. Thus, growth time and the amount of impurities could be reduced, and the cost of cell production could be lowered because fewer resources were required for the seed train. Furthermore, the inventors tested microcarriers and macrocarriers best suited for high H-1PV yield, cell proliferation, and bead-to-bead mobility, successfully scaling up the process from 24-well plates to Erlenmeyer flasks and spinner flasks, and utilizing large agitated tank bioreactors or fixed-bed bioreactors containing microcarriers, such as iCELLis® 500m 2 Production in this region is considered promising.

[0017] In summary, the present invention is a method for producing parvovirus H-1, (a) A step to prepare the producing cell line NB-324K, (b) A step of producing a seed train by growing NB-324K cells under appropriate conditions, (c) At the time of sowing, a step is taken to prepare a cell culture medium free of animal components supplemented with 2% animal serum, and a culture vessel containing a microcarrier or macrocarrier. (d) The step of seeding the NB-324K cells from step (b) into the culture vessel of step (c), (e) A step in which NB-324K cells are proliferated, (f) A step in which, at the time of infection, 100% of the culture medium is replaced with an animal component-free cell culture medium containing a microcarrier or macrocarrier, wherein the animal component-free cell culture medium is supplemented with 1% animal serum or is not supplemented with animal serum. (g) 3 to 8 days after infection, NB-324K cells are collected using a lysis buffer containing 1 to 100 mM Tris, 1 to 10 mM MgCl2, 2.5 to 10% TrypLE (trademark), pH 9 to 10, with or without 0.1 to 1% Tween (registered trademark) 80, the lysis buffer is stirred, and then washed with a washing buffer containing 1 to 100 mM Tris, 1 to 10 mM MgCl2, pH 9 to 10, wherein the lysis buffer and washing buffer are pooled together. (h) A step to remove impurities from the parvovirus recovered material by filtration, (i) A step of removing unencapsulated viral DNA and contaminated host cell DNA by DNase treatment, (j) A step of performing tangential flow filtration for buffer exchange and concentration, (k) A step of performing anion exchange chromatography to remove empty particles and most impurities, (l) A step of performing tangential flow filtration for buffer exchange and concentration to 0-3% Visipaque and 97-100% Ringer's solution, (m) Steps to obtain the final product of 48% Visipaque / Ringer's solution and A method that includes this.

[0018] In a preferred embodiment, in step (g), the lysis buffer comprises 25 mM Tris, 5 mM MgCl2, 5% TrypLE®, and pH 10.

[0019] In another preferred embodiment, in step (g), the washing step is carried out with a buffer containing 25 mM Tris, 5 mM MgCl2, pH 10, and step (g) yields a buffer containing 25 mM Tris, 5 mM MgCl2, 2.5% TrypLE®, and 0.1 to 1% Tween® 80, preferably less than 0.25% Tween® 80, or not.

[0020] In another preferred embodiment, in step (g), the treatment with the lysis buffer is carried out at 40°C for 1 hour with shaking at 70 rpm or without circulating CO2 in a bioreactor (w / o), and the treatment with the washing buffer is carried out for 1 minute with shaking at 70 rpm or without circulating CO2 in a bioreactor. [Brief explanation of the drawing]

[0021] [Figure 1] This figure shows an overview of the process timeline and FBS content using VP-SFM® medium. [Figure 2] This figure shows similar H-1PV-specific virus yields using 5% FBS or a two-step FBS reduction scheme. Here, 3.6E4 NB-324K cells / cm2 were seeded in VP-SFM™ medium supplemented with 5% or 2% FBS. After 3 days of cell proliferation, infection was performed at a MOI of 0.05, followed by a 100% medium change with 5% or 0% FBS. Cells were harvested and lysed 4 days after infection. [Figure 3] This figure shows the boost in H-1PV-specific virus yield by a three-stage FBS reduction using VP-SFM (trademark). Here, 5E3 NB-324K cells / cm2 were seeded in 2% FBS. After 3 days of cell proliferation, a first 100% medium change was performed to either 1% or 0% FBS, and infection at a MOI of 0.01 was carried out on the production phase I cells from days 3 to 5. Two days after infection, a second 100% medium change was performed without FBS on the production phase II cells from days 5 to 7. Cells were harvested on day 7, four days after infection, and lysed. [Figure 4]This figure shows a comparison of recovered samples using the Triton® X-100 process, a freeze-thaw process in viral Tris (VT) buffer, and with or without 0.25% Tween80, with or without 2.5% TrypLE pH10, and with 25 mM Tris and 5 mM MgCl2. NB-324K cells were seeded in a 175 cm² flask at 5E3 cells / cm² in VP-SFM® containing 2% FBS for 3 days, then 100% medium change to VP-SFM® containing 0% FBS and infected at an MOI of 0.05. Four days after infection, cells were washed with 1×PBS before lysis and recovered using different lysis methods. [Figure 5] This figure shows a microscopic observation of the cell bridge between confluent microcarriers and newly added microcarriers. a: Adhesion enhancement (10×); b: Cytodex® 1 (10×); scale bar = 200 μm [Figure 6a] This figure shows the H-1PV-specific virus yield screening using various carriers. Here, 4E4 NB-324K cells / cm2 were seeded in 24-well plates with a growth area of ​​10 cm2 / ml for each carrier (11.2 cm2 / ml for iC), and shaken at 100 rpm. Cells were harvested 4 days after infection and lysed. [Figure 6b] This figure shows H-1PV-specific virus yield screening after bead transfer using various carriers. 2E4 [black] or 4E4 [shaded] NB-324K cells / cm2 were seeded in 24-well plates with a growth area of ​​5 cm2 / ml for each microcarrier, and orbital shaking was performed at 100 rpm. After 3 days of cell growth, cells were infected with a MOI of 0.01, and the growth surface and volume of medium were doubled by adding new microcarriers to fresh medium, and then the medium volume and microcarrier density were returned to the initial conditions by dividing in a 1:2 ratio. Cells were harvested and lysed 4 days after infection. [Figure 7]This figure shows the H-1PV-specific virus yield after scaling up the best microcarriers and macrocarriers. Here, 2E4 NB-324K cells / cm2 were seeded in VP-SFM™ at a growth area of ​​10cm2 / ml (a: microcarrier EA or CD1; b: macrocarrier iC or FC) using 40ml per 125ml Erlenmeyer flask [blacked out] or 100ml per spinner flask [shaded]. Seeding was performed in four cycles of 1 minute at 40 rpm followed by 30 minutes at 0 rpm, for a total seeding time of 2 hours. Agitation was then set to 30-100 rpm for Erlenmeyer flasks or 40 rpm for spinner flasks. After 3 days of cell growth, cells were infected with a MOI of 0.01 and 50% of the medium was replaced with fresh medium. Cells were harvested and lysed 4 days after infection. [Figure 8] This figure shows the H-1PV-specific virus yield in iCELLis® nano using different fixed beds and their respective Tflask run controls. In separate bioreactor operations, 5E3 cells / cm2 (0.53m2) or 9E3 cells / cm2 (4m2) were seeded on iCELLis® nano fixed beds [blacked out] and Tflask run controls [shaded]. After 3 days of cell proliferation in VP-SFM® cell growth medium, the first 100% medium change was performed in VP-SFM® infection medium, and infection at a MOI of 0.01 was carried out on production phase I cells from day 3 to day 5. Two days after infection, the second 100% medium change was performed on production phase II cells from day 5 to day 7 in FBS-free VP-SFM® medium. Cells were harvested and lysed on day 7, four days after infection. [Modes for carrying out the invention]

[0022] The underlying technical problem of this invention is to further optimize the production of oncolytic protoparvovirus, preferably H-1PV, on a large scale, because currently available approaches do not provide a large-scale method that produces H-1PV with high viral yield while simultaneously reducing production costs and avoiding undesirable animal-derived products.

[0023] In experiments leading to the present invention, which aims to increase virus yield while reducing production costs and avoiding undesirable animal-derived products, VP-SFM™, an animal component-free cell culture medium supplemented with 5% FBS during seeding and infection, was compared with VP-SFM™, which was supplemented with 2% FBS during seeding and 0% FBS during infection.

[0024] In this regard, the term “cell culture” means the maintenance of cells in a population in vitro environment. Using the culture medium of the present invention, adherent mammalian cells, i.e., cells that adhere to a culture vessel, preferably epithelial cells, such as human neonatal kidney cells (NB-324K) (Tattersall 1983) transformed with simian virus 40, can be cultured and represent a “producing cell line.”

[0025] The terms "culture" or "proliferation" refer to the maintenance of cells in vitro under conditions favorable to their growth, differentiation, or continued survival, whether in an active or quiescent state.

[0026] The term "cell culture medium" refers to a nutrient solution used to culture cells.

[0027] The term "component" refers to any compound that may be used in a cell culture medium to maintain or promote the growth of cell proliferation, whether of chemical or biological origin. The terms "constituent," "nutrient," and "component" are interchangeable and all refer to such compounds. Typical components used in cell culture media include glucose, glutamine, glutamic acid, growth factors, insulin, and proteins.

[0028] The terms "animal component-free" or "serum-free" media refer to media that do not contain animal serum. Serum-free media are distinguished from low-serum media that contain serum and media that are essentially serum-free. More specifically, the terms "serum," or rather "animal serum," refer to, for example, heat-inactivated fetal bovine serum (FBS; Biowest, France).

[0029] The process of the present invention uses an "animal component-free cell culture medium" containing glucose, glutamine, glutamic acid, and proteins (e.g., growth factors, insulin, etc.), which can support the culture of epithelial cells, preferably NB-324K cells, in vitro for the production of H-1PV.

[0030] The culture medium of the present invention can be used to promote the high-density growth of human epithelial cells, preferably NB-324K cells, and / or to increase parvovirus production. In one preferred embodiment, the process of the present invention uses an animal component-free cell culture medium comprising 16-22 mM glucose, 3-5 mM glutamine, 0.1-0.6 mM glutamic acid, 0.5-1.0 mM lactate, less than 0.3 mM ammonium, and 3-10 mg / ml protein, which can support the culture of NB-324K cells for H-1PV production.

[0031] Preferably, the animal component-free cell culture medium contains 17-20 mM glucose, about 4 mM glutamine, about 0.15-0.5 mM glutamic acid, about 0.7 mM lactate, less than 0.2 mM ammonium, and 4-8 mg / ml of protein, such as supplements, epidermal growth factor, and insulin.

[0032] In a particular preferred embodiment, the animal component-free cell culture medium contains 19.14 mM glucose, 4.25 mM glutamine, 0.174 mM glutamic acid, 0.669 mM lactate, less than 0.05 mM ammonium, and about 5 mg / ml of protein. These proteins include EGF, insulin, and protein supplements. This medium is called VP-SFM® (Thermofisher, USA).

[0033] Therefore, according to the present invention, NB-324K cells are cultured in VP-SFM® medium. In a more specific embodiment, NB-324K cells are cultured in a 5% CO2 atmosphere at 37°C.

[0034] In a further embodiment, the cell culture medium is supplemented with 100 U / ml penicillin, 100 μg / ml streptomycin, and 3–5 mM L-glutamine (Thermofisher, USA). Finally, VP-SFM™ medium supplemented with 4 mM glutamine is preferred because higher concentrations do not lead to increased viral yield and therefore reduce production costs (see Table 1).

[0035] [Table 1]

[0036] In the experiments resulting from this invention, NB-324K cells were cultured in VP-SFM® medium containing 0%, 1%, 2%, or 5% FBS (see Table 1), but seeded with 5% or 2% FBS added for production. Similar virus yields were shown with VP-SFM® with 5% FBS added for seeding and production, compared to VP-SFM® with 2% FBS added for seeding and 0% FBS added for production (see Figure 2). Therefore, according to this invention, VP-SFM® medium with 2% FBS added is preferred, and the method of this invention preferably begins with 5% FBS in the seed train. As already stated above, VP-SFM® medium with 2% FBS added at seeding and 0% FBS added at infection is preferred over 5% FBS because it yields similar virus yields and reduces the amount of FBS by up to 80% (see Figure 2). Therefore, by applying the method described herein for producing H-1PV with high viral yield, production costs can be reduced while simultaneously avoiding undesirable animal-derived products.

[0037] Regarding viral infection in the method of the present invention, a viral stock of wild-type H-1PV is used to infect NB-324K cells, preferably at a rate of 0.5 to 5 × 10⁶ per cell. 2 Plaque-forming units (PFUs), or rather, 0.01 or 0.05 PFUs per cell (PFU / cell) MOI, are used for infection. According to the present invention, NB-324K cells are infected with H-1PV at the time of seeding ("simultaneous" seeding and infection), or NB-324K cells are infected with H-1PV 2 to 6 days after the start of cell proliferation, preferably 3 to 6 days later ("non-simultaneous" seeding and infection).

[0038] In a particular embodiment of the present invention, NB-324K cells are divided into 2.0 × 10⁶ cells. 4 ~5.0×10 4 cells / cm 2are infected with parvovirus at a cell density of, and the time of infection (TOI) is either at the time of seeding ("simultaneous" seeding and infection) or after 2 to 6 days of cell growth, preferably 3 to 6 days after the start of cell growth of NB-324K cells ("non-simultaneous" seeding and infection).

[0039] For simultaneous seeding and infection, the NB-324K cells of the present invention are seeded into a culture vessel pre-laid with animal component-free cell culture medium supplemented with 2% animal serum (the animal component-free cell culture medium is VP-SFM™ medium). In a particular embodiment of the present invention, NB-324K cells are cultured at 2.0×10 4 ~5.0×10 4 cells / cm 2 , preferably 4.0×10 4 cells / cm 2 are infected at a cell density of. In a further specific embodiment, the cells are harvested 3 to 5 days after infection, preferably 4 days after infection.

[0040] For non-simultaneous seeding and infection, the NB-324K cells of the present invention are seeded into a culture vessel pre-laid with animal component-free cell culture medium supplemented with 2% animal serum (the animal component-free cell culture medium is VP-SFM™ medium). In a specific embodiment, the inventors then allowed the cells to grow for 2 to 6 days, preferably 3 to 6 days ("cell growth"). After 2 to 6 days of cell growth, preferably 3 to 6 days, the animal component-free cell culture medium supplemented with 2% animal serum is completely replaced with fresh animal component-free cell culture medium supplemented with 0%, 1% or 2% FBS, preferably 0% or 1% FBS (the fresh animal component-free cell culture medium is VP-SFM™ medium) (the "2-0-0% FBS" and "2-1-0% FBS" strategies) ("100% medium exchange"). At the same time, NB-324K cells are infected with a virus stock of wild-type H-1PV. In a preferred embodiment, 0.5×10 2 ~5×10 2 The cells are infected with parvovirus at an MOI of PFU / cell, rather 0.01 or 0.05 PFU / cell. In a particular embodiment of the present invention, 5.0×10 3 ~8.0×103 cells / cm 2 Preferably 5.0 × 10 3 or 8.0 × 10 3 cells / cm 2 , more comfortable 5.0×10 3 cells / cm 2 Seedlings are made at a cell density of NB-324K cells. In a preferred embodiment, a wild-type H-1PV virus stock is placed in a new animal component-free cell culture medium with a 100% medium change. Therefore, for non-simultaneous seeding and infection, TOI is 2-6 days after cell proliferation, preferably 3-6 days after cell proliferation of NB-324K cells has started. In a specific embodiment, another medium change to 0% FBS is made on day 2 post-infection, and cells are harvested 3-5 days after infection, preferably 4 days after infection (see Figure 1).

[0041] Comparing simultaneous and non-simultaneous seeding and infection processes, the seeding density was 2.0 × 10⁻⁶. 4 ~5.0×10 4 cells / cm 2 From 5.0 x 10 3 ~8.0×10 3 cells / cm 2 Since this reduces the seeding density, a non-synchronous seeding and infection process is preferred according to the present invention. By adapting the VP-SFM® medium to a non-synchronous seeding and infection process, the seeding density can be reduced to 8.0 × 10⁻⁶. 3 From 5.0 x 10 3 Since the cell count was reduced again to cells / cm, non-simultaneous infection is preferable. In this way, cell proliferation is suppressed, the resources required for seed training are reduced, and production costs are lowered.

[0042] To avoid undesirable animal-derived products, the inventors compared a two-step FBS reduction strategy using one or two 100% medium changes with a three-step FBS reduction strategy. Figure 1 outlines all medium change strategies: the "5-5% FBS", "2-0% FBS", "2-1-0% FBS", and "2-0-0% FBS" strategies.

[0043] According to the present invention, all strategies preferably begin with a method for culturing or growing NB-324K cells, which are grown in a seed train using 5% FBS, and then transferred to a culture vessel pre-lined with animal component-free cell culture medium supplemented with 2% animal serum, and grown for 2 to 6 days, preferably 3 to 6 days. After 2 to 6 days, preferably 3 to 6 days of cell growth, a 100% medium change is performed once. As already mentioned above, the time of infection (TOI) is either at the time of seeding or after 2 to 6 days, preferably 3 to 6 days of cell growth, i.e., at a time other than the 100% medium change. The 100% medium change is performed with new animal component-free cell culture medium supplemented with 0%, 1%, or 2% FBS, preferably 0% or 1% FBS (the new animal component-free cell culture medium is VP-SFM® medium) (see the "2-0-0%FBS" or "2-1-0%FBS" strategies in Figure 3). By applying a two-step process, for example, when infecting with 0% FBS (2-0% FBS), the inventors detected that a virus yield comparable to that obtained with 5% FBS (5-5% FBS) could be obtained throughout the entire process (see Figure 2). Therefore, according to the present invention, the method is performed with at least one 100% medium exchange with a new animal component-free cell culture medium supplemented with 0% FBS.

[0044] In the three-stage strategy, a single 100% medium change was performed with fresh animal component-free cell culture medium supplemented with 0% or 1% FBS, 2–6 days after seeding, preferably 3–6 days, or rather, after cell proliferation began, followed by another 100% medium change with fresh animal component-free cell culture medium without FBS, 1–3 days after infection, preferably 2 days ("2-1-0% FBS" or "2-0-0% FBS"). Applying 2-1-0% FBS in the three-stage strategy resulted in approximately 0.3 log PFU / cm² compared to the 2-0-0% FBS strategy. 2 An increase in (see Figure 3) is shown, and therefore, the 2-1-0% FBS strategy is preferred in the present invention. In summary, the highest virus yield is achieved by applying the 2-1-0% FBS strategy, and FBS depletion in the manner claimed herein is feasible.

[0045] Therefore, the method of the present invention preferably uses the optimized culture medium VP-SFM™ suitable for FBS-free production, and a medium exchange strategy of at least two steps to reduce the amount of FBS required for FBS-free recovery by up to 80% at an equivalent virus yield. By adding a medium exchange on day 2 post-infection and reducing the FBS in three steps from 2% to 1% and then to 0%, an increase in production of approximately 0.3 log was achieved, and the required FBS could be reduced by up to 40%. By applying this strategy in experiments resulting from the present invention, it was possible to achieve high virus production yield and lower impurities for downstream processes in the FBS-free recovery.

[0046] To simplify large-scale H-1PV production using adherent cells such as the anchorage-dependent production cell line NB-324K, the inventors utilized carriers. In one preferred embodiment, microcarriers are prepared for suspension culture, and macrocarriers are intended for fixed-bed bioreactors. Thus, the term “carrier” in this invention is used when both systems are discussed. The characterizations of the microcarriers and macrocarriers according to the present invention are shown in Table 2, respectively.

[0047] [Table 2]

[0048] For simultaneous seeding and infection according to the present invention, the inventors prepared culture vessels pre-lined with microcarriers or macrocarriers in animal component-free cell culture medium supplemented with 2% animal serum, preferably. Subsequently, the method of the present invention is carried out as described above. In short, NB-324K cells grown in a seed train with 5% FBS added are added to a culture vessel pre-lined with animal component-free cell culture medium supplemented with 2% animal serum and microcarriers or macrocarriers, and the NB-324K cells are injected with a wild-type H-1PV virus stock, preferably 0.5 × 10⁶ 2 ~5×102 Infection is carried out with a PFU / cell, or rather, with an MOI of 0.01 or 0.05 PFU / cell. According to the present invention, NB-324K cells are seeded and 2.0 × 10 4 ~5.0×10 4 cells / cm 2 Preferably 4.0 × 10 4 cells / cm 2 The cells are infected with parvovirus at the specified cell density, and the cells are collected 3 to 5 days after infection, preferably on the 4th day after infection.

[0049] For simultaneous sowing and infection, the inventors added approximately 8-12 cm per well. 2 Preferably about 9.5 to 11.5 cm 2 , more preferably 10 cm 2 Or 11.3cm 2 We propose adding a carrier.

[0050] For non-synchronous seeding and infection, the inventors prepared culture vessels pre-lined with microcarriers or macrocarriers in a cell culture medium, preferably free of animal components, supplemented with 2% animal serum. The method of the present invention is then carried out as described above. In short, NB-324K cells grown in 5% FBS in a seed train are added to a culture vessel pre-lined with a cell culture medium free of animal components supplemented with 2% animal serum and microcarriers or macrocarriers. According to the present invention, the inventors then allow the cells to grow for 2 to 6 days, preferably 3 to 6 days ("cell proliferation"). After 2 to 6 days of cell proliferation, preferably 3 to 6 days later, the cell culture medium free of animal components supplemented with 2% animal serum is completely replaced with a new cell culture medium free of animal components supplemented with 1% FBS and fresh microcarriers, preferably so that the total growth area doubles ("100% medium change"). In another preferred embodiment, the wild-type H-1PV virus stock is also contained in a fresh, animal component-free cell culture medium with a 100% medium change. Therefore, for non-synchronous seeding and infection, the time of infection (TOI) is 2–6 days after cell proliferation, preferably 3–6 days after cell proliferation of NB-324K cells begins. The medium change to 0% FBS is performed 1–3 days after cell infection, preferably 2 days after cell infection. In a specific embodiment, cells are harvested 3–5 days after TOI, i.e., after infection, preferably 4 days after infection (see Figure 1).

[0051] For non-simultaneous seeding and infection, the inventors have provided approximately 4-6 cm per well. 2 Preferably 5 cm 2 I propose adding a carrier.

[0052] As already mentioned above, the characterizations of the microcarriers and macrocarriers according to the present invention are shown in Table 2, respectively. With the exception of the porous Cytopore® 1 and Cytopore® 2, all microcarriers showed satisfactory cell proliferation. Furthermore, all microcarriers showed promising bead-to-bead migration ability during cell proliferation and virus production, and by adding fresh microcarriers, further cell proliferation is possible, skipping the trypsin treatment step.

[0053] Therefore, according to the present invention, the ability of bead transfer without trypsin treatment suggests good cell proliferation capacity in scaled-up seed trains, and thus it is preferable to use non-porous microcarriers.

[0054] To find a preferred carrier, a wide range of parameters were tested, including seeding and process agitation, carrier density, cell seeding density, MOI, TOI, presence or absence of bead transfer, cell culture volume per container, and medium exchange plan (Tables 3 and 4). The results of virus production on carriers for preferred carrier selection are summarized in Figures 6a and 6b.

[0055] [Table 3]

[0056] [Table 4]

[0057] Therefore, in one preferred embodiment of the present invention, the microcarrier is a crosslinked dextran matrix (Cytodex® 1; CD1) having positively charged DEAE (N,N-diethylaminoethyl) groups distributed throughout the matrix. In another preferred embodiment of the present invention, the microcarrier represents "Adhesion-Enhanced CellBIND®" (EA, an adhesion-enhanced surface treatment in which oxygen is injected into the surface of the microcarrier). In an alternative preferred embodiment, the macrocarrier is polypropylene and polyester nonwoven fibers (Fibra-Cel®; FC) or iCELLis® (iC; or iC-500m 2 It is a nonwoven hydrophilic polyethylene terephthalate (PET) macrocarrier from ).

[0058] For simultaneous and non-simultaneous seeding and infection, microcarrier CD1 and macrocarrier iC represent preferred carriers in one embodiment of the present invention. Furthermore, macrocarriers FC and iC exhibit good production yields in suspension culture and fixed-bed bioreactors, and since higher production yields are achieved in fixed-bed bioreactors, they represent alternative preferred embodiments of the present invention.

[0059] By applying the method of the present invention, the majority of infectious viral particles remain bound to cells upon recovery. For H-1PV recovery, freeze-thaw cell lysis in Tris-EDTA buffer (VTE) (Leuchs 2016) or Tris-HCl buffer (VT) (Leuchs 2017) has been previously reported for static cultures. However, the freeze-thaw method is limited to large-scale production using adherent cells on carriers; therefore, a cell lysis method that can be scaled up is required. Accordingly, an alternative cell lysis method was developed in the experiments resulting from the present invention. In one embodiment, the present invention refers to cell lysis using a lysis buffer containing Tris, MgCl2, and recombinant cell dissociation enzyme TrypLE® together with Tween® 80, which is more environmentally friendly than Triton® X-100 and achieves similar or higher production yields. However, Tween® 80 can be omitted from the lysis buffer recipe without adversely affecting the virus yield.

[0060] According to the present invention, the lysis of NB-324K cells in step (g) is carried out 3 to 5 days after infection using a "lysis buffer" containing 1 to 100 mM Tris, 1 to 10 mM MgCl2, 2.5 to 10% TrypLE (trademark), and pH 9 to 10, with or without 0.1 to 1% Tween (registered trademark) 80, preferably using a lysis buffer containing 25 mM Tris, 5 mM MgCl2, and 5% TrypLE (trademark) pH 10, at 40°C for 1 hour without CO2.

[0061] According to the present invention, after dissolution in the dissolution buffer in step (g), washing is performed with a “washing buffer” containing 1 to 100 mM Tris, 1 to 10 mM MgCl2, pH 9 to 10, preferably a washing buffer containing 25 mM Tris, 5 mM MgCl2, pH 10, and the dissolution buffer and washing buffer are pooled together, and the dissolution step and washing step, i.e., step (g) of the present invention, produce a buffer containing 0.1 to 1% Tween® 80, preferably less than 0.25% Tween® 80, or not, 1 to 100 mM Tris, preferably 25 mM Tris; 1 to 10 mM MgCl2, preferably 5 mM MgCl2; 2.5 to 10% TrypLE®, preferably 2.5% TrypLE®, pH 10.

[0062] "TrypLE (trademark)" is a reagent containing a highly purified recombinant cell dissociation enzyme that serves as an alternative to porcine trypsin (GIBCO, USA).

[0063] In summary, culture medium optimization and a three-step medium exchange strategy, as well as recovery using a lysis buffer containing or without Tween® 80, preferably without Tween® 80, Tris, MgCl2, and recombinant cell dissociation enzyme TrypLE®, provide a solid foundation for scaling up production.

[0064] In summary, using the optimized cell culture medium VP-SFM™ and a novel medium exchange strategy, the inventors established reduced seeded cell density and FBS, resulting in FBS-free recovery. The tested carriers were best suited for high H-1PV yield, cell proliferation, and bead-to-bead transport. The inventors also demonstrated viable carrier-based production and successfully scaled up the process from 24-well plates to Erlenmeyer flasks, spinner flasks, and iCellis nano.

[0065] The following examples are intended to illustrate the present invention and not to limit it. While these examples are typical of what may be used, other methods known to those skilled in the art may be used instead. [Examples]

[0066] material and method Cell lines and cell culture media NB-324K human neonatal kidney cells transformed with simian virus 40 (Tattersall 1983) were cultured in VP-SFM® medium (Thermofisher, USA) containing 5% FBS at 37°C under a 5% CO2 atmosphere. The cell culture medium was supplemented with 100 U / ml penicillin, 100 μg / ml streptomycin, and 4 mM L-glutamine (see Table 1).

[0067] Virus stock, infection period Cells were infected with a self-produced and purified wild-type H-1PV virus stock at an MOI of 0.01 or 0.05 plaque-forming units (PFUs) per cell. The time of infection (TOI) was either at seeding (simultaneous infection and seeding) or 3–6 days (non-simultaneous infection) based on Countess cell count.

[0068] Cell culture and virus production in static culture Simultaneous dissemination and infection: 3.6E4 cells / cm² 2 The cells were seeded and simultaneously infected in T175 flasks containing VP-SFM (trademark) completely free of FBS (see Table 1). Cells were harvested 4 days after infection (dpi).

[0069] Non-simultaneous dissemination and infection: 7.9E3 cells / cm² 2The cells were seeded in T175 flasks containing either VP-SFM® Full Medium or VP-SFM® Cell Growth Medium (see Table 1). After 3 days of cell growth, the medium was completely replaced with FBS-free VP-SFM® or VP-SFM® infection medium. Simultaneously, the cells were infected with an MOI of 0.01 or 0.05 according to the Countess cell count in the reference T175 flask. On post-infection day 2, cells that had been in VP-SFM® infection medium since day 3 underwent another 100% medium change with FBS-free VP-SFM®. On post-infection day 4, the cells were harvested by freeze-thaw cycle.

[0070] Career adjustment The characterization of microcarriers and macrocarriers (referred to as "carriers" when discussing both systems) is shown in Table 2. Microcarriers were handled and stored in silicone-treated bottles with Sigmacote (Sigma-Aldrich, Germany) according to the manufacturer's instructions. Non-cationic microcarriers were hydrated and autoclaved in aqua ad. injectable (B. Braun, Germany), and cationic microcarriers were treated with Ca 2+ and Mg 2+ The macrocarriers were hydrated and autoclaved in 1×PBS (without ) according to the manufacturer's instructions. The macrocarriers were sterile upon supply and hydrated in cell culture medium at 37°C for 30 minutes before use.

[0071] Cell culture and production systems for carriers Screening in 24-well plates: Carrier screening experiments were performed using a Max Q 2000 CO2Plus (ThermoFisher Scientific, USA) with 1 ml of VP-SFM (trademark) per well in a 24-well ultra-low adhesion plate (Corning, Germany) at 37°C, 5% CO2, and orbital stirring at 100 rpm. The static control was treated similarly to the carrier samples, but in a 6-well plate (9.6 cm²). 2 In the growth area, 2 ml of cell culture medium was used per well, and the seeds were seeded without agitation.

[0072] For simultaneous sowing and infection, 10 cm 2 Or 11.3cm 2 Carriers (macroscarriers from iCELLis®, cut in half) were added to each of the three wells. Then, 4E4 cells / cm³ were added. 2 One ml of VP-SFM® complete solution containing NB-324K cells, equivalent to the seeding density, was added to each well and infected at an MOI of 0.01. Cells were harvested four days after infection using Triton® X-100.

[0073] For non-simultaneous seeding and infection, 5 cm per well in 2 wells. 2 The growth area was then added. Then, 2E4 or 4E4 cells / cm² 2 One ml of VP-SFM® complete medium containing NB-324K cells, corresponding to the seeding density, was added to each well. On day 3, both wells were pooled per carrier, and nuclei derived from the sample were counted. Fresh VP-SFM® complete medium containing the virus and fresh carrier was added, and the total growth area for each pool was increased to 10 cm². 2 20cm 2 The cells were then infected by doubling the cell culture volume from 2 ml to 4 ml (MOI of 0.01). The pool of used and fresh carriers was then filled to 5 cm³ per well. 2 The cells were divided into three wells, each containing 1 ml of cell culture medium and having a growth area. Cells were harvested on day 7, four days after infection, using Triton® X-100.

[0074] Microcarriers in Erlenmeyer flask: After screening, adhesion-enhanced (EA) and Cytodex® 1 (CD1) microcarriers were added to a 10cm³ flask containing 40ml of VP-SFM® complete solution using a Max Q 2000 CO2Plus (ThermoFisher Scientific, USA) at 37°C, 5% CO2, and orbital stirring at 60-70 rpm. 2This was selected for upscaling experiments in a 125 ml Erlenmeyer flask with a growth area of ​​2E4 cells / cm². 2 The cells were seeded, and stirring was reduced to 0 rpm for 30 minutes or 30 rpm for 3 hours to promote cell adhesion. On day 3, samples were taken, and cell density was determined by nucleus count for virus infection (MOI of 0.01), and the virus was added during a 50% medium change on the same day with fresh VP-SFM®.

[0075] Virus production in Erlenmeyer flasks using macrocarriers Macrocarriers from Fibra-Cel® and iCELLis® were also tested in 125 ml Erlenmeyer flasks using the same parameters as those described for microcarriers. However, orbital stirring was performed at 30–100 rpm, and stirring during sowing was either at 100 rpm or 40 rpm for 1 minute, followed by 0 rpm for 30 minutes, repeated four times for a total sowing time of 2 hours.

[0076] Virus production in a spinner flask using a carrier EA and CD1 microcarriers were placed in a 250 ml spinner flask (Integra Biosciences, Switzerland), and macrocarriers from Fibra-Cel® and iCELLis® were placed in a 500 ml spinner flask (Integra Biosciences, Switzerland), with 100 ml of VP-SFM® for complete use and 10 cm. 2 The growth area was further scaled up at 37°C, 5% CO2, and with stirring at 15-30 rpm. Subsequently, 2E4 cells / cm² were used. 2The cells were seeded, and stirring was reduced to 0 rpm for 30 minutes, or to 40 rpm for 1 minute, then to 0 rpm for 30 minutes, repeating this cycle four times for a total seeding time of 2 hours. On day 3, samples were taken, and cell density was determined by nucleus count for viral infection (MOI of 0.01 or 0.05). The virus was then added during a 50% medium change on the same day with VP-SFM® complete medium. Cells were harvested 4 days after infection.

[0077] iCELLis® Nano-based virus production iCELLis (registered trademark) nanosystem, 0.53m 2 and 4m 2 The test was conducted using the fixed bed size. After preparing the fixed bed according to the manufacturer's instructions, the bioreactor was filled with 850 ml of VP-SFM® cell growth medium supplemented with 2% FBS. 4m 2 A recirculation loop was connected to the fixed bed to supply an additional 3150 ml of VP-SFM® cell growth medium. Then, 5E3 cells / cm³ were added. 2 0.53m 2 In a fixed bed, or 9E3 cells / cm² 2 4m 2 The cells were seeded on a fixed bed and maintained at 37°C, pH 7.3, and over 30-40% dissolved oxygen. After 3-6 days of cell proliferation, several macrocarriers were removed from the top of the fixed bed, the cells were counted, and then infected at a MOI of 0.01 during a 100% medium change to VP-SFM® infection medium supplemented with 1% FBS. Two days after infection, an additional 100% medium change was performed to VP-SFM® medium without FBS. Cells were harvested four days after infection.

[0078] collect For carrier cultures seeded in wells, Erlenmeyer flasks, or spinner flasks, remove the cell culture medium 4 days after infection, and then lyse with 0.02 ml / cm³ for cell lysis. 2 The samples were treated with 1% Triton® X-100, 0.1M Tris, pH 9.5 at 37°C for 30 minutes.

[0079] For iCELLis® nanocultures, the cell culture medium was removed 4 days after infection. Then, the cells in the fixed bed were rinsed with PBS and 0.094 ml / cm³ containing or without 0.5% Tween® 80. 2 (0.53m 2 ) or 0.014 ml / cm³ 2 (4m 2 The solution can be dissolved in 25 mM Tris, 5 mM MgCl2, 5% TrypLE® pH 10 lysis buffer without CO2 at 40°C for 1 hour, and then rinsed with 25 mM Tris, 5 mM MgCl2, pH 10 washing buffer. The dissolved and washed solutions are pooled together to obtain 25 mM Tris, 5 mM MgCl2, 2.5% TrypLE® pH 10, which may or may not contain 0.25% Tween® 80, preferably without Tween® 80.

[0080] Cell lysis was performed via a freeze / thaw process for static culture. The culture medium was removed and the infected cells were washed with 1×PBS. The culture medium supernatant and detached cells were centrifuged at 5000×g for 5 minutes. The pellet was washed with PBS and hydrated at 0.02 ml / cm³. 2 The cells were resuspended in 0.05 M Tris-HCl, pH 8.7 (VT) at 37°C for 30 minutes and subjected to three freeze (liquid nitrogen) and thaw (37°C) cycles. In addition, the following steps were performed during medium optimization and FBS reduction: After centrifugation at 5000 × g for 5 minutes, the cell fragments were discarded. The cell lysates were then sonicated at 48 W for 1 minute using a Sonorex Super 10P ultrasonic homogenizer (Bandelin, Germany), 5 mM MgCl2 was added, and then treated with DNAse (50 U / ml, Sigma, Germany) at 37°C for 30 minutes to remove uncapsidized viral DNA and contaminating host cell DNA.

[0081] Quantification of virus yield The virus was quantified by performing a plaque formation assay on infectious particles (see Leuchs (2016) for a description of the method). [Examples]

[0082] Comparison of a two-stage FBS reduction strategy using 100% medium change versus a three-stage FBS reduction strategy. Subsequently, the inventors compared a two-step FBS reduction strategy using 100% medium change with a three-step FBS reduction strategy. See Figure 1 for an overview of all medium change strategies using VP-SFM® medium. All strategies began with 5% FBS in the seed train, followed by cell growth in 5% or 2% FBS for 3 days, and then 100% medium change and simultaneous infection on day 3 after seeding. In the two-step process, infection with 0% FBS (2-0%) resulted in a 1.0E7 PFU / cm² 2 The resulting virus yield was comparable to that of the 5% FBS-added (5-5%) strategy throughout the entire process (see Figure 2). In the three-stage strategy, a 100% medium change was performed 3 days after seeding with 2% FBS, with the addition of either 1% FBS (2-1-0%) or no FBS (2-0-0%), followed by a second 100% medium change without FBS on day 5 for both strategies. Three independent experiments showed that the 2-1-0% FBS strategy yielded 7.7E7 PFU / cm³ higher than the 2-0-0% FBS strategy. 2 Up to approximately 0.3 log PFU / cm 2 An increase was demonstrated (Figure 3). In summary, the results show that FBS depletion throughout the process is achievable at the highest viral yield achieved by applying the 2-1-0% FBS strategy. However, FBS contains components necessary for high viral yield that cannot be supplied by VP-SFM (trademark) alone. [Examples]

[0083] Chemical cell lysis required for large-scale H-1PV recovery In the method of the present invention, the majority of infectious virus particles are bound to cells upon recovery. For the recovery of H-1PV, freeze-thaw cell lysis in Tris-EDTA buffer (VTE) (Leuchs 2016) or Tris-HCl buffer (VT) (Leuchs 2017) has been previously reported for static cultures. Large-scale production using adherent cells on carriers requires scalable cell lysis. Therefore, a lysis buffer containing Tris, MgCl2, and recombinant cell dissociation enzyme TrypLE®, with or without Tween® 80, is used to achieve >2.0E7 PFU / cm². 2 We developed an alternative cell lysis method that yields a satisfactory viral yield (see Figure 4).

[0084] In summary, media optimization, along with a three-step medium exchange strategy using lysis buffers containing Triton® X-100 lysis or Tween® 80, or not, Tris, MgCl2, and recombinant cell dissociation enzymes, provides a solid foundation for scaling up production. [Examples]

[0085] Screening of cell proliferation on microcarriers and macrocarriers on a 24-well scale is possible as cell transfer between beads is feasible. For large-scale production using adherent cells, microcarriers for suspension culture or macrocarriers for fixed-bed bioreactors can be used. The inventors screened 11 carriers for cell proliferation, bead transfer ability, and virus yield. Direct cell counting in the carriers was difficult; therefore, glucose consumption was measured as an indicator of proliferation.

[0086] Several cell lines can construct individual cell bridges from confluent microcarriers to new microcarriers for continuous cell proliferation. This inter-bead transfer facilitates seed-train cell proliferation without trypsin treatment, as it only requires the addition of new microcarriers. To test the inter-bead transfer capability, cells were seeded onto microcarriers and additional microcarriers were added with fresh cell culture medium by dividing them 1:2 on days 4 and 7. Trypan blue cell counting of microcarriers after trypsin treatment was performed on day 4 and day 10, prior to the 1:2 division. Figure 5 shows inter-bead transfer using cell bridges with microcarriers EA and CD1. The trypsin-free inter-bead transfer capability suggests good cell proliferation capacity in scaled-up seed-trains using NB-324K cells. [Examples]

[0087] Macrocarriers from Cytodex® and iCELLis® exhibit the highest H-1PV yield. After characterizing cell proliferation on the carrier, the inventors applied different production strategies (with or without bead transfer, synchronous / non-synchronous seeding and infection) to identify the conditions best suited for high H-1PV virus production.

[0088] Simultaneous infection and seeding of carriers in 24-well ultra-low adhesion plates yielded similar viral yields for most microcarriers (HII, SP, P, PP, EA, SII, CP1, CP2). The highest yields were achieved with microcarrier CD1 and macrocarrier iC, at 3.4E7 PFU / cm², respectively. 2 and 2.0E7PFU / cm 2 (See Figure 6a). The macrocarrier FC was 4.2E6PFU / cm 2 This was the lowest yield.

[0089] Due to non-simultaneous dissemination and infection, 4E4 cells / cm² 2 In addition to density, there was a 50% reduction in 2E4 cells / cm³. 2 The seeding density was tested for higher yield. Three days after seeding, cells were infected, and to maintain volume and microcarrier density, 1:2 division, fresh cell culture medium, and microcarriers were added for inter-bead transfer. The virus yield was 4E4 cells / cm³. 2 The highest seeding density was observed at 4E4 cells / cm², and this was similar for most microcarriers compared to simultaneous seeding and infection without inter-bead transfer, except for solid HII and porous CP1 and CP2 carriers (see Figure 6b). In summary, high virus production appears to be possible with all tested strategies, but not at 4E4 cells / cm². 2 This seeding density is required. In addition, HII and porous microcarriers CP1 and CP2 showed high yields only with simultaneous infection and seeding without inter-bead migration.

[0090] Using two selected microcarriers and two macrocarriers, we investigated scaling up from a 24-well plate format to Erlenmeyer flasks and spinner flasks up to 100 ml. Microcarrier CD1 showed the highest yield, but the surface of microcarrier EA yielded comparable results to a 10-layer CellSTACK® chamber. Due to the limitations of small-scale testing in 24-well plates, both macrocarriers for fixed-bed bioreactors were also selected for scale-up experiments. A wide range of parameters were tested, including seeding and process agitation, carrier density, cell seeding density, MOI, TOI, presence or absence of bead transfer, cell culture volume per container, and medium exchange plan (see Tables 3 and 4). However, only the most promising parameters are shown for 40 ml of cell culture medium in an Erlenmeyer flask and 100 ml in a spinner flask (see Figures 7a and 7b).

[0091] The microcarrier CD1 was 4.3E7 PFU / cm in the Erlenmeyer flask. 2yield level was achieved, but when scaled up in a spinner flask, the yield decreased by 1 log. Microcarrier EA had lower virus yield than CD1 in all systems.

[0092] Macrocarriers iC and FC in Erlenmeyer flasks, with a macrocarrier density of 10 cm 2 / ml, and a total cell surface area of 400 cm 2 achieved a virus yield of 3.0E7 PFU / cm 2 . However, when scaled up to a spinner flask, the yield was no higher than 1.0E6 PFU / cm 2 at a density of 10 cm / ml and a cell surface area of 1000 cm 2 2 . The results for CD1 and both macrocarriers in Erlenmeyer flasks confirmed that high virus yields are possible in suspension, making these carriers the leading candidates for further scale-up. [Example]

[0093] First production in iCELLis® nano Assuming a yield of 3.0E7 PFU / cm generated in Erlenmeyer flasks 2 , a batch yield of 1.5E14 PFU can be expected for the iCELLis® 500 m 2 fixed bed (equivalent to 15,000 doses of 1E10 PFU per dose). Therefore, virus production was tested in the downscaled iCELLis® nano system.

[0094] For production in the iCELLis® nano benchtop bioreactor, the newly developed medium exchange strategy 2-1-0% FBS was used. Here, fixed bed sizes of 0.53 m 2 and 4 m 2 were tested, yielding 3.7E6 PFU / cm 2 and 5.7E6 PFU / cm 2 ​The following results were obtained (see Figure 8). Yields were similar in both fixed beds, but were approximately one log step lower than those from macrocarriers from iCELLis® in the Erlenmeyer flask and steady-state run control.

[0095] List of References Angelova AL, Aprahamian M, Balboni G, Delecluse HJ, Feederle R, Kiprianova I, Grekova SP, Galabov AS, Witzens-Harig M, Ho AD, Rommelaere J, Raykov Z (2009a) Oncolytic rat parvovirus h-1pv, a candidate for the treatment of human lymphoma: In vitro and in vivo studies. Mol Ther 17(7):1164-72 doi:10.1038 / mt.2009.78 Angelova AL, Aprahamian M, Grekova SP, Hajri A, Leuchs B, Giese NA, Dinsart C, Herrmann A, Balboni G, Rommelaere J, Raykov Z (2009b) Improvement of gemcitabine-based therapy of pancreatic carcinoma by means of oncolytic parvovirus h-1pv. Clin Cancer Res 15(2):511-9 doi:10.1158 / 1078-0432.CCR-08-1088 Cotmore SF, Agbandje-McKenna M, Chiorini JA, Mukha DV, Pintel DJ, Qiu J, Soderlund-Venermo M, Tattersall P, Tijssen P, Gatherer D, Davison AJ (2014) The family parvoviridae. Arch Virol 159(5):1239-47 doi:10.1007 / s00705-013-1914-1 Dupressoir T, Vanacker JM, Cornelis JJ, Duponchel N, Rommelaere J (1989) Inhibition by parvovirus h-1 of the formation of tumors in nude mice and colonies in vitro by transformed human mammary epithelial cells. Cancer Res 49(12):3203-8 Faisst S, Guittard D, Benner A, Cesbron JY, Schlehofer JR, Rommelaere J, Dupressoir T (1998) Dose-dependent regression of hela cell-derived tumours in scid mice after parvovirus h-1 infection. Int J Cancer 75(4):584-9 doi:10.1002 / (sici)1097-0215(19980209)75:4<584::aid-ijc15>3.0.co;2-9 Fukuhara H, Ino Y, Todo T (2016) Oncolytic virus therapy: A new era of cancer treatment at dawn. Cancer Sci 107(10):1373-1379 doi:10.1111 / cas.13027 Geletneky K, Hajda J, Angelova AL, Leuchs B, Capper D, Bartsch AJ, Neumann JO, Schoning T, Husing J, Beelte B, Kiprianova I, Roscher M, Bhat R, von Deimling A, Bruck W, Just A, Frehtman V, Lobhard S, Terletskaia-Ladwig E, Fry J, Jochims K, Daniel V, Krebs O, Dahm M, Huber B, Unterberg A, Rommelaere J (2017) Oncolytic h-1 parvovirus shows safety and signs of immunogenic activity in a first phase i / iia glioblastoma trial. Mol Ther 25(12):2620-2634 doi:10.1016 / j.ymthe.2017.08.016 Geletneky K, Huesing J, Rommelaere J, Schlehofer JR, Leuchs B, Dahm M, Krebs O, von Knebel Doeberitz M, Huber B, Hajda J (2012) Phase i / iia study of intratumoral / intracerebral or intravenous / intracerebral administration of parvovirus h-1 (parvoryx) in patients with progressive primary or recurrent glioblastoma multiforme: Parvoryx01 protocol. BMC Cancer 12:99 doi:10.1186 / 1471-2407-12-99 Geletneky K, Kiprianova I, Ayache A, Koch R, Herrero YCM, Deleu L, Sommer C, Thomas N, Rommelaere J, Schlehofer JR (2010) Regression of advanced rat and human gliomas by local or systemic treatment with oncolytic parvovirus h-1 in rat models. Neuro Oncol 12(8):804-14 doi:10.1093 / neuonc / noq023 Hajda J, Leuchs B, Angelova AL, Frehtman V, Rommelaere J, Mertens M, Pilz M, Kieser M, Krebs O, Dahm M, Huber B, Engeland CE, Mavratzas A, Hohmann N, Schreiber J, Jager D, Halama N, Sedlaczek O, Gaida MM, Daniel V, Springfeld C, Ungerechts G (2021) Phase 2 trial of oncolytic h-1 parvovirus therapy shows safety and signs of immune system activation in patients with metastatic pancreatic ductal adenocarcinoma. Clin Cancer Res doi:10.1158 / 1078-0432.CCR-21-1020 Leuchs B, Frehtman V, Riese M, Muller M, Rommelaere J (2017) A novel scalable, robust downstream process for oncolytic rat parvovirus: Isoelectric point-based elimination of empty particles. Appl Microbiol Biotechnol 101(8):3143-3152 doi:10.1007 / s00253-016-8071-x Leuchs B, Roscher M, Muller M, Kurschner K, Rommelaere J (2016) Standardized large-scale h-1pv production process with efficient quality and quantity monitoring. J Virol Methods 229:48-59 doi:10.1016 / j.jviromet.2015.11.022 Liu S, Ruban L, Wang Y, Zhou Y, Nesbeth DN (2017) Establishing elements of a synthetic biology platform for vaccinia virus production: Biobrick design, serum-free virus production and microcarrier-based cultivation of cv-1 cells. Heliyon 3(2):e00238 doi:10.1016 / j.heliyon.2017.e00238 Martinez JAA, Milian JVF, Ueti MW, Rojas-Martinez C (2020) Innovative alternatives for continuous in vitro culture of babesia bigemina in medium free of components of animal origin. Pathogens 9(5) doi:ARTN 343 10.3390 / pathogens9050343 Nuesch JP, Lacroix J, Marchini A, Rommelaere J (2012) Molecular pathways: Rodent parvoviruses--mechanisms of oncolysis and prospects for clinical cancer treatment. Clin Cancer Res 18(13):3516-23 doi:10.1158 / 1078-0432.CCR-11-2325 Rommelaere J, Geletneky K, Angelova AL, Daeffler L, Dinsart C, Kiprianova I, Schlehofer JR, Raykov Z (2010) Oncolytic parvoviruses as cancer therapeutics. Cytokine Growth Factor Rev 21(2-3):185-95 doi:10.1016 / j.cytogfr.2010.02.011 Rourou S, van der Ark A, van der Velden T, Kallel H (2007) A microcarrier cell culture process for propagating rabies virus in vero cells grown in a stirred bioreactor under fully animal component free conditions. Vaccine 25(19):3879-3889 doi:10.1016 / j.vaccine.2007.01.086 Stewart B, Wild C (2014) World cancer report 2014. International Agency for Research on Cancer Tattersall P, Bratton J (1983) Reciprocal productive and restrictive virus-cell interactions of immunosuppressive and prototype strains of minute virus of mice. J Virol 46(3):944-55 Tree JA, Richardson C, Fooks AR, Clegg JC, Looby D (2001) Comparison of large-scale mammalian cell culture systems with egg culture for the production of influenza virus a vaccine strains. Vaccine 19(25-26):3444-50 doi:10.1016 / s0264-410x(01)00053-6 van der Valk J, Bieback K, Buta C, Cochrane B, Dirks WG, Fu J, Hickman JJ, Hohensee C, Kolar R, Liebsch M, Pistollato F, Schulz M, Thieme D, Weber T, Wiest J, Winkler S, Gstraunthaler G (2018) Fetal bovine serum (fbs): Past - present - future. ALTEX 35(1):99-118 doi:10.14573 / altex.1705101 Wu SC, Huang GYL, Liu JH (2002) Production of retrovirus and adenovirus vectors for gene therapy: A comparative study using microcarrier and stationary cell culture. Biotechnol Prog 18(3):617-622 doi:10.1021 / bp020026p

Claims

1. A method for producing parvovirus H-1 (H-1PV), (a) A step to prepare the producing cell line NB-324K, (b) A step of producing a seed train by growing the NB-324K cells under appropriate conditions, (c) At the time of sowing, a step is taken to prepare a cell culture medium free of animal components supplemented with 2% animal serum, and a culture vessel containing a microcarrier or macrocarrier, (d) The step of seeding the NB-324K cells of step (b) into the culture vessel, (e) A step of cell proliferation of the NB-324K cells, (f) A step of replacing 100% of the culture medium with an animal component-free cell culture medium containing a microcarrier or macrocarrier at the time of infection, wherein the animal component-free cell culture medium is supplemented with 1% animal serum or is not supplemented with animal serum. (g) 3-8 days post-infection, 1-100mM Tris, 1-10mM MgCl 2 The NB-324K cells were recovered using a lysis buffer containing 2.5-10% recombinant cell dissociation enzyme as a substitute for porcine trypsin and pH 9-10. The lysis buffer was then stirred, followed by 1-100 mM Tris and 1-10 mM MgCl. 2 a step of washing with a washing buffer containing pH 9 to 10, wherein the lysis buffer and the washing buffer are pooled together, (h) A step to remove impurities from the parvovirus recovered material by filtration, (i) A step of removing unencapsulated viral DNA and contaminated host cell DNA by DNase treatment, (j) A step of performing tangential flow filtration for buffer exchange and concentration, (k) A step of performing anion exchange chromatography to remove empty particles and most impurities, (l) A step of performing tangential flow filtration for buffer exchange to Ringer's solution, and the following steps (m) Final production step with 48% iodixanol in Ringer's solution and A method that includes this.

2. In step (g), the lysis buffer is 25 mM Tris, 5 mM MgCl 2 , comprising 5% recombinant cell dissociation enzyme as a substitute for porcine trypsin, pH 10, and treatment with the lysis buffer is CO 2 The method according to claim 1, which does not include and is carried out at 40°C for 1 hour.

3. In step (g), the washing step involves 25 mM Tris and 5 mM MgCl 2 The procedure was carried out in a buffer solution containing pH 10, and step (g) involved 25 mM Tris and 5 mM MgCl. 2 The method according to claim 1 or 2, wherein a buffer containing a recombinant cell dissociation enzyme as an alternative to 2.5% porcine trypsin is provided.

4. The method according to claim 1 or 2, wherein the microcarriers are a crosslinked dextran matrix having positively charged DEAE (N,N-diethylaminoethyl) groups distributed throughout the matrix, or adhesion-enhancing (EA) microcarriers having a negative surface charge.

5. The method according to claim 1 or 2, wherein the macrocarrier is a polypropylene and polyester nonwoven fiber or a nonwoven hydrophilic polyethylene terephthalate (PET) macrocarrier.

6. When the NB-324K cells are seeded and infected in step (d), the seeding is performed at a density of 2.0×10 4 to 5.0×10 4 cells / cm 2 , or when the infection occurs 2 to 6 days after cell proliferation in step (e), the seeding is performed at a seeding cell density of 5.0×10 3 to 8.0×10 3 cells / cm 2 . The method according to claim 5.

7. The method according to claim 1 or 2, wherein the animal serum is heat-inactivated fetal bovine serum (FBS).

8. The method according to claim 1 or 2, wherein a second 100% medium exchange without supplementation with animal serum is performed after step (f).

9. The method according to claim 8, wherein the medium for 100% medium replacement in step (f) is either to which 1% FBS is added or to which FBS is not added, and the second medium for 100% medium replacement is to which FBS is not added.

10. The method according to claim 8, wherein the second 100% culture medium replacement is performed 1 to 3 days after infection.

11. The method according to claim 1 or 2, wherein the animal component-free cell culture medium is a virus-producing serum-free medium containing 16-22 mM glucose, 3-5 mM glutamine, 0.1-0.6 mM glutamic acid, 0.5-1.0 mM lactate, less than 0.3 mM ammonium, and 3-10 μg / μl protein.

12. The method according to claim 11, wherein the animal component-free cell culture medium is the virus-producing serum-free medium to which 4 mM L-glutamine is added.

13. The method according to claim 1 or 2, wherein the method is initiated at 5% FBS in the seed train.

14. Cell lysis is caused by Tris, MgCl 2 The method according to claim 1 or 2, wherein the procedure is carried out in a buffer containing a recombinant cell dissociation enzyme as an alternative to porcine trypsin and pH 10.

15. The method according to claim 1 or 2, wherein the method is used for suspension culture or a fixed-bed bioreactor.

Citation Information

Patent Citations

  • virus production process

    JP2002513583A

  • Method for mass production and purification of parvovirus

    JP2018523992A

  • Optimized method for large-scale production of parvovirus H-1 in essentially serum-free medium

    JP2019531071A

  • A scalable method for the production and purification of oncolytic rat parvovirus H-1 based on isoelectric exclusion of empty particles

    JP2019534020A